| Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction T Kondo, R Campbell, PS Jhund, IS Anand, PE Carson, CSP Lam, ... JACC: Heart Failure, 2024 | | 2024 |
| Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function S Matsumoto, AD Henderson, L Shen, M Yang, K Swedberg, ... Journal of the American College of Cardiology 83 (24), 2426-2436, 2024 | 1 | 2024 |
| Loop diuretic utilisation with or without heart failure: impact on prognosis JM Friday, JGF Cleland, P Pellicori, M Wolters, JJV McMurray, PS Jhund, ... European Heart Journal, ehae345, 2024 | | 2024 |
| Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF P Dewan, L Shen, J Pedro Ferreira, PS Jhund, IS Anand, A Chandra, ... Circulation, 2024 | | 2024 |
| Sex Differences in Heart Failure With Improved Ejection Fraction: The DELIVER Trial MA Pabón, X Wang, CSP Lam, E O’Meara, M Vaduganathan, BL Claggett, ... Heart Failure 12 (6), 1119-1122, 2024 | | 2024 |
| Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials L Shen, MMY Lee, PS Jhund, CB Granger, IS Anand, AP Maggioni, ... JAMA, 2024 | | 2024 |
| Dapagliflozin and days of full health lost in the DAPA-HF trial T Kondo, UM Mogensen, A Talebi, SB Gasparyan, RT Campbell, ... Journal of the American College of Cardiology 83 (20), 1973-1986, 2024 | 1 | 2024 |
| Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre … MCH Lassen, JW Ostrominski, SE Inzucchi, BL Claggett, I Kulac, P Jhund, ... European Journal of Heart Failure, 2024 | | 2024 |
| Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial M Vaduganathan, BL Claggett, CSP Lam, B Pitt, M Senni, SJ Shah, ... European Journal of Heart Failure, 2024 | 2 | 2024 |
| Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis JW Ostrominski, BL Claggett, ZM Miao, FR Mc Causland, IS Anand, ... Journal of the American College of Cardiology, 2024 | | 2024 |
| Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial SD Solomon, JW Ostrominski, M Vaduganathan, B Claggett, PS Jhund, ... European Journal of Heart Failure, 2024 | | 2024 |
| Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to US Adults with Heart Failure JW Ostrominski, R Aggarwal, BL Claggett, IJ Kulac, AS Desai, PS Jhund, ... Journal of Cardiac Failure, 2024 | | 2024 |
| Sacubitril/valsartan-related hypotension in patients with heart failure and preserved or mildly reduced ejection fraction A Foà, M Vaduganathan, BL Claggett, MA Pabon, H Lu, MA Pfeffer, ... Journal of the American College of Cardiology 83 (18), 1731-1739, 2024 | 3 | 2024 |
| A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials T Kondo, PS Jhund, SB Gasparyan, M Yang, BL Claggett, ... Nature Medicine, 1-8, 2024 | | 2024 |
| Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction M Yang, T Kondo, A Talebi, PS Jhund, KF Docherty, BL Claggett, ... European Journal of Heart Failure, 2024 | | 2024 |
| Use of medical therapy and risk of clinical events according to frailty in heart failure patients-A real-life cohort study. JE Strange, E Fosbøl, CH Garred, M Elmegaard, C Andersson, PS Jhund, ... European Journal of Heart Failure, 2024 | | 2024 |
| Measuring congestion with a non‐invasive monitoring device in heart failure and haemodialysis: CONGEST‐HF JP Curtain, A Talebi, A McIntosh, A McConnachie, J O'Donnell, P Welsh, ... European Journal of Heart Failure, 2024 | | 2024 |
| Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction K McDowell, T Kondo, A Talebi, K Teh, E Bachus, RA De Boer, ... JAMA cardiology 9 (5), 457-465, 2024 | | 2024 |
| Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design J Carberry, MC Petrie, MMY Lee, K Brooksbank, RT Campbell, R Good, ... ESC Heart Failure, 2024 | | 2024 |
| Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER JH Butt, PS Jhund, KF Docherty, BL Claggett, M Vaduganathan, E Bachus, ... JACC: Heart Failure, 2024 | | 2024 |
John McMurrayUniversity of Glasgow.在 glasgow.ac.uk 的电子邮件经过验证
